A PCSK9 Missense Variant Associated with a Reduced Risk of Early-Onset Myocardial Infarction

Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease

Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181

Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans

Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138

A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease

the CARDIoGRAMplusC4D Consortium (2015) · Nature Genetics · doi:10.1038/ng.3396 · Cited by 2,447

A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins

Goldstein, J. L., & Brown, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.01.036 · Cited by 1,233

Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants

Myocardial Infarction Genetics Consortium (2009) · Nature Genetics · doi:10.1038/ng.327 · Cited by 1,088

Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease

Ference, B. A., Yoo, W., Alesh, I., Mahajan, N., Mirowska, K. K., Mewada, A., Kahn, J., Afonso, L., Williams, K. A., & Flack, J. M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.017 · Cited by 898

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 781

Health Benefits of the Mediterranean Diet: Metabolic and Molecular Mechanisms

Tosti, V., Bertozzi, B., & Fontana, L. (2018) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glx227 · Cited by 762

PCSK9: a convertase that coordinates LDL catabolism

Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800091-jlr200 · Cited by 533

Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study

Dewey, F. E., Murray, M. F., Overton, J. D., Habegger, L., Leader, J. B., Fetterolf, S. N., O’Dushlaine, C. T., Hout, C. V. V., Staples, J. C., Gonzaga-Jauregui, C. G., et al. (2016) · Science · doi:10.1126/science.aaf6814 · Cited by 545

Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease

Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507652 · Cited by 493

New susceptibility locus for coronary artery disease on chromosome 3q22.3

Italian Atherosclerosis, T., Erdmann, J., Myocardial Infarction Genetics Consortium, Wellcome Trust Case Control Consortium, Cardiogenics Consortium, Großhennig, A., Braund, P. S., König, I. R., Hengstenberg, C., Hall, A. S., et al. (2009) · Nature Genetics · doi:10.1038/ng.307 · Cited by 484

PCSK9 inhibitors: clinical evidence and implementation

Sabatine, M. S. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0107-8 · Cited by 338

PCSK9 is a critical regulator of the innate immune response and septic shock outcome

Walley, K. R., Thain, K. R., Russell, J. A., Reilly, M. P., Meyer, N. J., Ferguson, J. F., Christie, J. D., Nakada, T., Fjell, C. D., Thair, S. A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008782 · Cited by 366

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia

Grundy, S. M. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 353

A decade of genome-wide association studies for coronary artery disease: the challenges ahead

Erdmann, J., Kessler, T., Venegas, L. M., & Schunkert, H. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy084 · Cited by 331

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report

Grundy, S. M., Arai, H., Barter, P. J., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A. M., Davidson, M. H., Genest, J. J., Kesäniemi, Y. A., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 334

PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease

Benn, M., Nordestgaard, B. G., Grande, P., Schnohr, P., & Tybjærg-Hansen, A. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.044 · Cited by 317

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease

Abifadel, M., Rabès, J., Devillers, M., Münnich, A., Erlich, D., Junien, C., Varret, M., & Boileau, C. (2009) · Human Mutation · doi:10.1002/humu.20882 · Cited by 260

Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616

Ballantyne, C. M., Banka, P., Méndez, G., Garcia, R., Rosenstock, J., Rodgers, A., Mendizabal, G., Mitchel, Y., & Catapano, A. L. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.018 · Cited by 234

Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials

Guedeney, P., Giustino, G., Sorrentino, S., Claessen, B. E., Camaj, A., Kalkman, D. N., Vogel, B., Sartori, S., De Rosa, S., Baber, U., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehz430 · Cited by 208

Molecular basis of PCSK9 function

Lambert, G. C., Charlton, F., Rye, K., & Piper, D. E. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.06.010 · Cited by 201

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

Sabatine, M. S., Giugliano, R. P., Keech, A., Honarpour, N., Wang, H., Liu, T., Wasserman, S. M., Scott, R., Sever, P. S., & Pedersen, T. R. (2016) · American Heart Journal · doi:10.1016/j.ahj.2015.11.015 · Cited by 176

The dawn of a new era of targeted lipid-lowering therapies

Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171

Exome chip meta-analysis identifies novel loci and East Asian–specific coding variants that contribute to lipid levels and coronary artery disease

Lu, X., Peloso, G. M., Liu, D. J., Wu, Y., Zhang, H., Zhou, W., Li, J., Tang, C. S.-M., Dorajoo, R., Li, H., et al. (2017) · Nature Genetics · doi:10.1038/ng.3978 · Cited by 160

Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls

McLaren, P. J., Coulonges, C., Ripke, S., van den Berg, L. H., Buchbinder, S., Carrington, M. N., Cossarizza, A., Dalmau, J., Deeks, S. G., Delaneau, O., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003515 · Cited by 155

Thirty-five common variants for coronary artery disease: the fruits of much collaborative labour

Peden, J. F., & Farrall, M. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr384 · Cited by 147

Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering

Norata, G. D., Tavori, H., Pirillo, A., Fazio, S., & Catapano, A. L. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw194 · Cited by 147

Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies

Almontashiri, N. A. M., Vilmundarson, R. O., Ghasemzadeh, N., Dandona, S., Roberts, R., Quyyumi, A. A., Chen, H., & Stewart, A. F. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106294 · Cited by 109

Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention

Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109

Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs

Abifadel, M., Elbitar, S., Khoury, P. E., Ghaleb, Y., Chemaly, M., Moussalli, M.-L., Rabès, J., Varret, M., & Boileau, C. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0439-8 · Cited by 109

PCSK 9 plays a novel immunological role in oxidized LDL‐induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque

Liu, A., & Frostegård, J. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12758 · Cited by 98

Mendelian Randomisation Study of Childhood BMI and Early Menarche

Mumby, H. S., Elks, C. E., Li, S., Sharp, S. J., Khaw, K., Luben, R., Wareham, N. J., Loos, R. J. F., & Ong, K. K. (2011) · Journal of Obesity · doi:10.1155/2011/180729 · Cited by 94

PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites

Kent, S. T., Rosenson, R. S., Avery, C. L., Chen, Y.-D. I., Correa, A., Cummings, S. R., Cupples, L. A., Cushman, M., Evans, D. S., Gudnason, V., et al. (2017) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.116.001632 · Cited by 86

Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease

Nomura, A., Won, H., Khera, A. V., Takeuchi, F., Ito, K., McCarthy, S., Emdin, C. A., Klarin, D. M., Natarajan, P., Zekavat, S. M., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.311145 · Cited by 86

Contemporary Aspects of the Biology and Therapeutic Regulation of the Microsomal Triglyceride Transfer Protein

Hooper, A. J., Burnett, J. R., & Watts, G. F. (2014) · Circulation Research · doi:10.1161/circresaha.116.304637 · Cited by 89

Genetics of Coronary Artery Disease

Musunuru, K., & Kathiresan, S. (2010) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082509-141637 · Cited by 85

PCSK9 R46L, Lower LDL, and Cardiovascular Disease Risk in Familial Hypercholesterolemia

Saavedra, Y. G. L., Dufour, R., Davignon, J., & Baass, A. W. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304406 · Cited by 77

ABCC5, a Gene That Influences the Anterior Chamber Depth, Is Associated with Primary Angle Closure Glaucoma

Nongpiur, M. E., Khor, C. C., Jia, H., Cornes, B. K., Chen, L.-J., Qiao, C., Nair, K. S., Cheng, C., Xu, L., George, R. J., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004089 · Cited by 77

Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin

Gilchrist, S. C., Xu, F., Vega, G. L., Grundy, S. M., Chandalia, M., Lam, C., Lowe, R. S., Stepanavage, M. E., Musliner, T. A., Cohen, J. C., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1952 · Cited by 76

New Therapeutic Approaches to the Treatment of Dyslipidemia

Rader, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.005 · Cited by 75

Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials

Ridker, P. M., Amarenco, P., Brunell, R., Glynn, R. J., Jukema, J. W., Kastelein, J. J. P., Köenig, W., Nissen, S. E., Revkin, J. H., Santos, R. D., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.05.010 · Cited by 62

New Pharmacological Approaches to Target PCSK9

Catapano, A. L., Pirillo, A., & Norata, G. D. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00847-7 · Cited by 63

Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population

Guella, I., Asselta, R., Ardissino, D., Merlini, P. A., Peyvandi, F., Kathiresan, S., Mannucci, P. M., Marco Tubaro, U., & Duga, S. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m010009 · Cited by 59

Rare coding variants in 35 genes associate with circulating lipid levels—A multi-ancestry analysis of 170,000 exomes

Hindy, G., Dornbos, P., Chaffin, M. D., Liu, D. J., Wang, M., Selvaraj, M. S., Zhang, D., Park, J., Aguilar-Salinas, C. A., Fulton, L., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.11.021 · Cited by 56

Optimising the Detection and Management of Familial Hypercholesterolaemia: Central Role of Primary Care and its Integration with Specialist Services

Vickery, A. W., Bell, D. A., Garton‐Smith, J., Kirke, A. B., Pang, J., & Watts, G. F. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.07.062 · Cited by 55

PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels

Marais, A. D., Kim, J. B., Wasserman, S. M., & Lambert, G. C. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.004 · Cited by 55

Relationship Between Nonalcoholic Fatty Liver Disease Susceptibility Genes and Coronary Artery Disease

Brouwers, M. C. G. J., Simons, N., Stehouwer, C. D. A., Koek, G. H., Schaper, N. C., & Isaacs, A. J. (2019) · Hepatology Communications · doi:10.1002/hep4.1319 · Cited by 53

PCSK9: an emerging target for treatment of hypercholesterolemia

Duff, C. J., & Hooper, N. M. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.547480 · Cited by 50

A bibliometric analysis in gene research of myocardial infarction from 2001 to 2015

Zhou, H., Tan, W., Qiu, Z., Song, Y., & Gao, S. (2018) · PeerJ · doi:10.7717/peerj.4354 · Cited by 49

Established genetic risk factors do not distinguish early and later onset Crohnʼs disease

Essers, J. B., Lee, J. J., Kugathasan, S., Stevens, C. R., Grand, R. J., & Daly, M. J. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20922 · Cited by 50

Genetic variation inAPOB,PCSK9, andANGPTL3in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-Cl Levels

Huijgen, R., Sjouke, B., Vis, K., de Randamie, J. S. E., Defesche, J. C., Kastelein, J. J. P., Hovingh, G. K., & Fouchier, S. W. (2011) · Human Mutation · doi:10.1002/humu.21660 · Cited by 47

The role of PCSK9 in inflammation, immunity, and autoimmune diseases

Frostegård, J. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2017281 · Cited by 43

PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies

Khoury, P. E., Elbitar, S., Ghaleb, Y., Khalil, Y. A., Varret, M., Boileau, C., & Abifadel, M. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0684-8 · Cited by 46

Novel Therapeutic Targets for Managing Dyslipidemia

Sathiyakumar, V., Kapoor, K., Jones, S. R., Banach, M., Martin, S. S., & Toth, P. P. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.06.001 · Cited by 42

The Role of Early LDL Lowering to Prevent the Onset of Atherosclerotic Disease

Ference, B. A., & Mahajan, N. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0312-1 · Cited by 41

Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date

McCormack, T., Dent, R., & Blagden, M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12881 · Cited by 39

PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction

Puteri, M. U., Azmi, N. U., Kato, M., & Saputri, F. C. (2022) · Life · doi:10.3390/life12020190 · Cited by 40

Regional Distribution and Metabolic Effect of PCSK9 insLEU and R46L Gene Mutations and apoE Genotype

Awan, Z. A., DELVIN, E. E., Levy, E. H., Genest, J. J., Davignon, J., Seidah, N. G., & Baass, A. W. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.03.004 · Cited by 41

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)

Sobati, S., Shakouri, A., Edalati, M., Mohammadnejad, D., Parvan, R., Masoumi, J., & Abdolalizadeh, J. (2020) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2020.062 · Cited by 33

The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy

Feng, Q., Wei, W.-Q., Chung, C. P., Levinson, R. T., Bastarache, L. A., Denny, J. C., & Stein, C. M. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.3 · Cited by 41

PCSK9: Associated with cardiac diseases and their risk factors?

Guo, Y., Yan, B., Tai, S., Zhou, S., & Zheng, X. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108717 · Cited by 38

Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes.

Enas, E. A., Kuruvila, A. T., Khanna, P., Pitchumoni, C. S., & Mohan, V. (2013) · Europe PMC (PubMed Central) · Cited by 34

From lipid locus to drug target through human genomics

van der Laan, S. W., Harshfield, E. L., Hemerich, D., Stacey, D., Wood, A., & Asselbergs, F. W. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy120 · Cited by 33

Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-α: potential underlying mechanisms

Frostegård, J., Ahmed, S., Hafström, I., Ajeganova, S., & Rahman, M. (2021) · Arthritis Research & Therapy · doi:10.1186/s13075-020-02386-7 · Cited by 34

LDL Receptor Pathway Regulation by miR-224 and miR-520d

Salerno, A. G., van Solingen, C., Scotti, E., Wanschel, A. C. B. A., Afonso, M. S., Oldebeken, S. R., Spiro, W., Tontonoz, P., Rayner, K. J., & Moore, K. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00081 · Cited by 33

Genetic epidemiology of coronary artery disease: an Asian Indian perspective

Shanker, J., Maitra, A., & VIJAY, K. V. (2015) · Journal of Genetics · doi:10.1007/s12041-015-0547-4 · Cited by 33

Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus

Liu, A., Rahman, M., Hafström, I., Ajeganova, S., & Frostegård, J. (2020) · Lupus · doi:10.1177/0961203320926253 · Cited by 31

Disorders of Lipid Metabolism

Semenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00037-7 · Cited by 32

New developments in atherosclerosis: clinical potential of PCSK9 inhibition

Tavori, H., & Giunzioni, I. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s74692 · Cited by 29

Clinical Implications of Lipid Genetics for Cardiovascular Disease

Strong, A., & Rader, D. J. (2010) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-010-0131-7 · Cited by 29

Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes

Turner, T. A., & Stein, E. A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.004 · Cited by 28

PCSK9 as a therapeutic target for cardiovascular disease

Zhang, P.-Y. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4055 · Cited by 26

Genetic Polymorphisms in Sepsis and Cardiovascular Disease

Nakada, T., Takahashi, W., Nakada, E., Shimada, T., Russell, J. A., & Walley, K. R. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.01.003 · Cited by 26

Efficacy and safety of PCSK9 monoclonal antibodies

Iqbal, Z., Dhage, S. S., Mohamad, J. B., Abdel-Razik, A. E. S., Donn, R. P., Malik, R. A., Ho, J. H., Liu, Y., Adam, S., Isa, B., et al. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1681395 · Cited by 26

The Case for Treating Hypercholesterolemia at an Earlier Age

Steinberg, D. H., & Grundy, S. M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.016 · Cited by 23

Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials

Bai, J., Gong, L., Li, Q., & Wang, Z. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.01.004 · Cited by 25

Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy

Krittanawong, C., Khawaja, M., Rosenson, R. S., Amos, C. I., Nambi, V., Lavie, C. J., & Virani, S. S. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.101043 · Cited by 21

Screening and Identification of Pregnancy Zone Protein and Leucine‐Rich Alpha‐2‐Glycoprotein as Potential Serum Biomarkers for Early‐Onset Myocardial Infarction using Protein Profile Analysis

Xuan, C., Li, H., Li, L., Tian, Q., Wang, Q., Zhang, B., Guo, J., He, G., & Lun, L. (2018) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201800079 · Cited by 22

Genomics of hypertriglyceridemia

Tada, H., Takamura, M., & Kawashiri, M. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.12.005 · Cited by 22

Will Cholesteryl Ester Transfer Protein Inhibition Succeed Primarily by Lowering Low-Density Lipoprotein Cholesterol?

Kathiresan, S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.967 · Cited by 21

A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases

Chen, B., Shi, X., Cui, Y., Hou, A., & Zhao, P. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190809094203 · Cited by 22

Discovery and Validation of New Molecular Targets in Treating Dyslipidemia: The Role of Human Genetics

Khera, A. V., & Rader, D. J. (2009) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2009.12.003 · Cited by 19

LDL-Cholesterin und kardiovaskuläre Ereignisse: je niedriger desto besser?

Weitgasser, R., Ratzinger, M., Hemetsberger, M., & Siostrzonek, P. (2016) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-016-0518-2 · Cited by 19

Cigarette smoke extract stimulates PCSK9 production in HepG2 cells via ROS/NF‑κB signaling

Ma, B., Wang, X., Zhang, R., Niu, S., Rong, Z., Ni, L., Di, X., Han, Q., & Liu, C. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.11970 · Cited by 18

Genetic and epigenetic factors in the regulation of the immune response

Dahmer, M. K., Cornell, T. T., & Quasney, M. W. (2016) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000356 · Cited by 18

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives

Catapano, A. L., Pirillo, A., & Norata, G. D. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s130338 · Cited by 19

The HLA-B*57:01 allele corresponds to a very large MHC haploblock likely explaining its massive effect for HIV-1 elite control

Rahmouni, M., Marco, L. D., Spadoni, J., Tison, M., Santos, R. M., Labib, T., Noirel, J., Tamouza, R., Limou, S., Delaneau, O., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1305856 · Cited by 17

Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study

Miyoshi, T., Nakamura, K., Doi, M., & Ito, H. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0119-2 · Cited by 17

The transcription factor GATA-2 does not associate with angiographic coronary artery disease in the Ottawa Heart Genomics and Cleveland Clinic GeneBank Studies

Dandona, S., Chen, L., Fan, M., Alam, M. A., Assogba, O., Bélanger, M., Williams, K., Wells, G. A., Tang, W. H. W., Ellis, S. G., et al. (2009) · Human Genetics · doi:10.1007/s00439-009-0761-3 · Cited by 17

LDL-Cholesterol-Lowering Therapy

Pirillo, A., Norata, G. D., & Catapano, A. L. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_361 · Cited by 17

Regulation of Lipoprotein Homeostasis by Self-Assembling Peptides

Harbour, V., Casillas, C., Siddiqui, Z., Sarkar, B., Sanyal, S., Nguyen, P. K., Kim, K. K., Roy, A., Iglesias-Montoro, P., Patel, S., et al. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01229 · Cited by 16

Consensus statement on the management of dyslipidemia in Indian subjects: A different perspective

Enas, E. A., Dharmarajan, T. S., & Varkey, B. (2015) · Indian Heart Journal · doi:10.1016/j.ihj.2015.03.020 · Cited by 16

No large-effect low-frequency coding variation found for myocardial infarction

Holmen, O. L., Zhang, H., Zhou, W., Schmidt, E. M., Hovelson, D. H., Langhammer, A., Løchen, M., Ganesh, S. K., Mathiesen, E. B., VATTEN, L. J., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu175 · Cited by 14

Rare variants in long non-coding RNAs are associated with blood lipid levels in the TOPMed whole-genome sequencing study

Wang, Y., Selvaraj, M. S., Li, X., Li, Z., Holdcraft, J. A., Arnett, D. K., Bis, J. C., Blangero, J., Boerwinkle, E., Bowden, D. W., et al. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.09.003 · Cited by 14

High-throughput screening identifies MicroRNAs regulating human PCSK9 and hepatic low-density lipoprotein receptor expression

van Solingen, C., Oldebeken, S. R., Salerno, A. G., Wanschel, A. C. B. A., & Moore, K. J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.667298 · Cited by 11

Identification of PCSK9-like human gene knockouts using metabolomics, proteomics, and whole-genome sequencing in a consanguineous population

Belkadi, A., Thareja, G., Abbaszadeh, F., Badii, R., Fauman, E. B., Albagha, O., & Suhre, K. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100218 · Cited by 13

Meta-analyses of four eosinophil related gene variants in coronary heart disease

Lian, J., Huang, Y., Huang, R. S., Xu, L., Le, Y., Yang, X., Xu, W., Huang, X., Ye, M., Zhou, J., et al. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0862-z · Cited by 13

The clinical role of combined serum C1q and hsCRP in predicting coronary artery disease

Jia, Y., Wen, W., Yang, Y., Huang, M., Ning, Y., Jiao, X., Liu, S., Qin, Y., & Zhang, M. (2021) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2021.04.004 · Cited by 13

Estudio del componente genético de la cardiopatía isquémica: de los estudios de ligamiento al genotipado integral del genoma

Elosúa, R., Lluís-Ganella, C., & Lucas, G. (2009) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(09)71502-x · Cited by 13

Pooled DNA Resequencing of 68 Myocardial Infarction Candidate Genes in French Canadians

Beaudoin, M., Lo, K. S., N’Diaye, A., Rivas, M. A., Dubé, M., Laplante, N., Phillips, M. S., Rioux, J. D., Tardif, J., & Lettre, G. (2012) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.112.963165 · Cited by 13

A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction

Helgadóttir, A., Þorleifsson, G., Manolescu, A. R., Grétarsdóttir, S., Blöndal, T., Jónasdóttir, Á., Jonasdottir, A., Sigurðsson, Á., Baker, A., Pálsson, A., et al. (2007) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000279313.65556.85 · Cited by 83

Influence of 9p21.3 Genetic Variants on Clinical and Angiographic Outcomes in Early-Onset Myocardial Infarction

Ardissino, D., Berzuini, C., Merlini, P. A., Mannuccio Mannucci, P., Surti, A., Burtt, N., Voight, B., Tubaro, M., Peyvandi, F., Spreafico, M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.075 · Cited by 80

Association of the 9p21.3 Locus With Risk of First-Ever Myocardial Infarction in Pakistanis

Saleheen, D., Alexander, M., Rasheed, A., Wormser, D., Soranzo, N., Hammond, N., Butterworth, A. S., Zaidi, M. A., Haycock, P., Bumpstead, S., et al. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.197210 · Cited by 55

The Common Variant Rs9939609 In The FTO Gene Is Associated With Early-onset Myocardial Infarction (ABSTRACT).

Merlini, P., Berzuini, C., Mannucci, P. M., Peyvandi, F., Tubaro, M., Lina, D., Notarangelo, M. F., Foco, L., Bernardinelli, L., & Ardissino, D. (2008) · Research Explorer (The University of Manchester)

ASSOCIATION BETWEEN GENETIC VARIANTS IN PCSK9/ APOB/ LDLR AND PREMATURE MYOCARDIAL INFARCTION IN HAN CHINESE

Pu, T., Yu, H., Xu, M., & Gao, W. D. (2018) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(18)30655-7